Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key mediator of cell
death and inflammation. The unique hydrophobic pocket in the allosteric regulatory domain …

Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis,
NASH, fibrosis and, ultimately, cirrhosis. NAFLD is recognized as the hepatic component of …

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological change characterized by
the accumulation of triglycerides in hepatocytes and has frequently been associated with …

Fatty liver disease that develops in the absence of alcohol abuse is recognized increasingly
as a major health burden. This report summarizes the presentations and discussions at a …

Inherited factors play a major role in the predisposition to nonalcoholic fatty liver disease
(NAFLD), and the rs738409 C→ G polymorphism of PNPLA3/adiponutrin, encoding for the …

Genome-wide association studies and candidate gene studies have informed our
understanding of factors contributing to the well-recognized interindividual variation in the …

Insulin resistance is increasingly recognized as a chronic, low-level, inflammatory state.
Hyperinsulinemia and insulin action were initially proposed as the common preceding …

Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of liver disease in the
Western world. Furthermore, it is increasing worldwide, paralleling the obesity pandemic …